A Phase I, Partially-randomised, Partially Double-blinded, Safety, Tolerability and Pharmacokinetic Study of ABY-035 in Healthy Subjects and Psoriasis Patients

Trial Profile

A Phase I, Partially-randomised, Partially Double-blinded, Safety, Tolerability and Pharmacokinetic Study of ABY-035 in Healthy Subjects and Psoriasis Patients

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Oct 2016

At a glance

  • Drugs Interleukin-17 inhibitors (Primary) ; Interleukin-17 inhibitors (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions; First in man
  • Sponsors Affibody
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Oct 2016 Time frame of primary endpoint has been changed from Follow-up visit (Day 95) to Follow-up visit (Day 141). number of treatment arms and patients number also increases.
    • 07 Oct 2016 Planned number of patients changed from 58 to 64.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top